Inventurus Knowledge Solutions Limited has informed the Exchange regarding that the Board of Directors of the Company at its meeting held today, i.e., July 31, 2025, inter alia, approved the matters stated in the attached disclosure.
IKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Inventurus Knowledge Solutions (IKS Health) announced strong Q1 FY26 results on July 31, 2025. Consolidated revenue from operations rose to ₹7,400.95M from ₹6,400.93M in Q1 FY25 (~15.6% growth), while consolidated profit after tax jumped to ₹1,515.39M from ₹954.87M (~58.7% growth). Standalone revenue surged to ₹3,194.69M from ₹2,013.75M (~58.6% growth) with PAT at ₹1,128.75M vs ₹572.02M (~97% growth). Basic EPS nearly doubled to ₹9.07 from ₹5.75 on a consolidated basis. The board approved multiple leadership changes effective August 1, 2025: founder Mr. Sachin Gupta stepped down as Whole-time Director (citing personal reasons) and was redesignated as Non-Executive, Non-Independent Director while also being named Global CEO of the US subsidiary. CFO Ms. Nithya Balasubramanian was elevated to Whole-time Director for a 5-year term. Dr. Garheng Albert Kong (founder of HealthQuest Capital) joined as Independent Director. KKC & Associates LLP was re-appointed as Internal Auditor for FY 2025-26.
The strong earnings beat—especially the ~58% consolidated PAT growth and significant margin expansion—should support positive sentiment. The leadership transition looks orderly: a founder-led exit from executive role is balanced by elevation of the CFO and addition of a high-profile US healthcare investor as independent director, signalling strategic focus on US healthcare expansion (consistent with the recent ~$17M acquisition of a 48% stake in IKS WWMG MSO LLC).